(Mary Ann Liebert, Inc./Genetic Engineering News) Biotech and pharma companies are increasingly utilizing novel technologies to assess the druggability of test compounds early in the development cycle to avoid costly late clinical-stage attrition, according to Genetic Engineering and Biotechnology News.

By identifying absorption, distribution, metabolism, excretion, and toxicity issues early, pharma also has the opportunity to increase the probability of success of its new drug development activities and reduce the time to market, reports the May 1 issue of GEN.